Lifeboat Foundation

The BUGS that REVERSE Damage

A remarkable new study has successfully used the CRISPR-Cas9 gene editing technique to edit a specific gene in mice engineered to have fragile X syndrome (FXS), a single-gene disorder often related to autism. The single gene edit in the live mice resulted in significant improvements in repetitive and obsessive behaviors, making this the first time gene editing has been used to effectively target behavioral symptoms related to autism spectrum disorder (ASD).

FXS is a genetic disorder associated with intellectual disability, seizures and exaggerated repetitive behavior. Previous studies have shown that the repetitive behaviors associated with FXS are related to a specific excitatory receptor in the brain that, when dysregulated, causes exaggerated signaling between cells.

The CRISPR technique homes in on the gene that controls that excitatory receptor, the metabotropic glutamate receptor 5 (mGluR5), and essentially disables it, dampening the excessive signaling the corresponds with repetitive behaviors. In mice treated with the new system, obsessive digging behavior was reduced by 30 percent and repetitive leaping actions dropped by 70 percent.

For the first time ever researchers have had a breakthrough in creating a cocktail of drugs that caused new neurons to grow in the brains of mice.

In my last article I gave a detailed account on the debate of neurogenesis. While some neuroscientists claim that neurogenesis takes place within the adult mammalian human brain other researchers contest that idea claiming that new neurons stop developing at a very young age. Whichever side of the debate you are on one thing remains certain, that there are neurological diseases that leave negative impacts on cognitive function. This has left researchers looking for various ways to treat Alzheimer’s, Parkinson’s, and other brain damage.

Continue reading “Experimental Drug Injection Causes the Brain to Grow New Neurons” »

Often, different biohacking scenes reflect the different societies and cultures in which they develop. So, for example, European biohackers generally differ from their North American counterparts. North American groups are concerned with developing alternatives to the established healthcare practices. European groups, meanwhile, are more focused on finding ways of helping people in developing countries or engaging in artistic bio-projects.

Sweden’s deep relationship with digital technology helps explain why its biohacking scene is so unique.

Continue reading “Thousands of Swedes are inserting microchips into themselves – here’s why” »

A group of researchers from Yale University and Agilent Technologies have developed a #syntheticbiology technique that turns bacterium E. Coli into a phosphorylated protein factory capable of churning out every known instance of this modification in human proteins.

Proteins, the end product of genes, carry out life functions. Most human proteins are modified by a process called serine phosphorylation — a chemical switch that can alter their structure and function. Malfunctions in this process have been implicated in diseases such as cancer and Alzheimer’s yet are difficult to detect and study. A group of researchers from Yale University and Agilent Technologies have developed a synthetic biology technique that turns bacterium E. Coli into a phosphorylated protein factory capable of churning out every known instance of this modification in human proteins.

“We synthesized over 110,000 phosphoproteins from scratch and we can now study how they all function together,” said Jesse Rinehart, associate professor of cellular and molecular physiology at the Systems Biology Institute and senior author of the research. “This is the future of scientific research — we can build everything we study.”

Continue reading “New platform will help create designer human proteins in the lab” »

Researchers tissue-engineered human pancreatic islets in a laboratory that develop a circulatory system, secrete hormones like insulin and successfully treat sudden-onset type 1 diabetes in transplanted mice.

In a study published by Cell Reports, the scientists use a new bioengineering process they developed called a self-condensation cell culture. The technology helps nudge medical science closer to one day growing human organ tissues from a person’s own cells for regenerative therapy, say study investigators at Cincinnati Children’s Hospital Medical Center in the U.S. and Yokohama City University (YCU) in Japan.

“This method may serve as a principal curative strategy for treating type 1 diabetes, of which there are 79,000 new diagnoses per year,” said Takanori Takebe, MD, a physician-scientist at the Cincinnati Children’s Center for Stem Cell and Organoid Medicine. “This is a life-threatening disease that never goes away, so developing effective and possibly permanent therapeutic approaches would help millions of children and adults around the world.”

Continue reading “Tissue-engineered human pancreatic cells successfully treat diabetic mice” »

Investigators at Harvard Medical School have identified the key cellular mechanisms behind vascular aging and its effects on muscle health, and they have successfully reversed the process in animals.

The scientists used a chemical compound that’s an NAD+ booster called NMN which plays a critical role in repairing cellular DNA as well as maintaining cell vitality to test what would happen.

Could reversing the aging of blood vessels hold the key to restoring youthful vitality? If the old adage “you are as old as your arteries” reigns true then the answer is yes, at least in mice.

Continue reading “Harvard Rewinds the Biological Clock of Time” »

Two recently published studies are raising new concerns that the breakthrough CRISPR-Cas9 gene editing system could potentially trigger an increased cancer risk in cells edited using the technique. With human trials using the gene-editing technique set to commence this year, the scientists behind these new studies urge researchers to be aware of this newly discovered and dangerous cancer-driving mechanism.

It has been less than a decade since the revolutionary CRISPR-Cas9 gene-editing technique was discovered, allowing scientists an unprecedented way to accurately edit DNA. For the most part, the technique has proved promising, safe and effective. Last year, a controversial study was published claiming the technique could introduce unintended, off-target mutations, but after a flurry of criticism attacking the veracity of the work it was ultimately retracted.

These two new studies raise entirely new concerns regarding the technique’s potential for triggering cancer in edited cells. One study comes from a collaboration between the University of Cambridge and the Karolinska Institutet, while the other is led by a team of researchers at pharmaceutical company Novartis.